280 related articles for article (PubMed ID: 21708958)
1. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.
Fu T; He Q; Sharma P
Cancer Res; 2011 Aug; 71(16):5445-54. PubMed ID: 21708958
[TBL] [Abstract][Full Text] [Related]
2. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
3. Inducible costimulator ligand regulates bleomycin-induced lung and skin fibrosis in a mouse model independently of the inducible costimulator/inducible costimulator ligand pathway.
Tanaka C; Fujimoto M; Hamaguchi Y; Sato S; Takehara K; Hasegawa M
Arthritis Rheum; 2010 Jun; 62(6):1723-32. PubMed ID: 20191584
[TBL] [Abstract][Full Text] [Related]
4. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
5. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
6. CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.
Chen H; Fu T; Suh WK; Tsavachidou D; Wen S; Gao J; Ng Tang D; He Q; Sun J; Sharma P
Cancer Immunol Res; 2014 Feb; 2(2):167-76. PubMed ID: 24778280
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade.
Guillonneau C; Aubry V; Renaudin K; Séveno C; Usal C; Tezuka K; Anegon I
Transplantation; 2005 Aug; 80(4):546-54. PubMed ID: 16220623
[TBL] [Abstract][Full Text] [Related]
8. Inducible costimulator (ICOS) blockade inhibits accumulation of polyfunctional T helper 1/T helper 17 cells and mitigates autoimmune arthritis.
Frey O; Meisel J; Hutloff A; Bonhagen K; Bruns L; Kroczek RA; Morawietz L; Kamradt T
Ann Rheum Dis; 2010 Aug; 69(8):1495-501. PubMed ID: 20498202
[TBL] [Abstract][Full Text] [Related]
9. Th1 cytokine responses fail to effectively control Chlamydia lung infection in ICOS ligand knockout mice.
Kadkhoda K; Wang S; Joyee AG; Fan Y; Yang J; Yang X
J Immunol; 2010 Apr; 184(7):3780-8. PubMed ID: 20190137
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade.
Guillonneau C; Aubry V; Renaudin K; Séveno C; Usal C; Tezuka K; Anegon I
Transplantation; 2005 Jul; 80(2):255-63. PubMed ID: 16041272
[TBL] [Abstract][Full Text] [Related]
11. CD28/CTLA-4--CD80/CD86 and ICOS--B7RP-1 costimulatory pathway in bronchial asthma.
Chen YQ; Shi HZ
Allergy; 2006 Jan; 61(1):15-26. PubMed ID: 16364152
[TBL] [Abstract][Full Text] [Related]
12. Inducible co-stimulatory molecule ligand is protective during the induction and effector phases of crescentic glomerulonephritis.
Odobasic D; Kitching AR; Semple TJ; Holdsworth SR
J Am Soc Nephrol; 2006 Apr; 17(4):1044-53. PubMed ID: 16540559
[TBL] [Abstract][Full Text] [Related]
13. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems.
Gregor PD; Wolchok JD; Ferrone CR; Buchinshky H; Guevara-Patiño JA; Perales MA; Mortazavi F; Bacich D; Heston W; Latouche JB; Sadelain M; Allison JP; Scher HI; Houghton AN
Vaccine; 2004 Apr; 22(13-14):1700-8. PubMed ID: 15068853
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
[TBL] [Abstract][Full Text] [Related]
15. Critical role of inducible costimulator signaling in the development of arteriosclerosis.
Kosuge H; Suzuki J; Haraguchi G; Koga N; Maejima Y; Inobe M; Isobe M; Uede T
Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2660-5. PubMed ID: 16990558
[TBL] [Abstract][Full Text] [Related]
16. Importance of the inducible costimulator molecule for the induction of allergic immune responses and its decreased expression on T helper cells after venom immunotherapy.
Bellinghausen I; Klostermann B; Böttcher I; Knop J; Saloga J
Immunology; 2004 May; 112(1):80-6. PubMed ID: 15096187
[TBL] [Abstract][Full Text] [Related]
17. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection.
Ozkaynak E; Gao W; Shemmeri N; Wang C; Gutierrez-Ramos JC; Amaral J; Qin S; Rottman JB; Coyle AJ; Hancock WW
Nat Immunol; 2001 Jul; 2(7):591-6. PubMed ID: 11429542
[TBL] [Abstract][Full Text] [Related]
18. Endothelial inducible costimulator ligand expression is increased during human cardiac allograft rejection and regulates endothelial cell-dependent allo-activation of CD8+ T cells in vitro.
Klingenberg R; Autschbach F; Gleissner C; Giese T; Wambsganss N; Sommer N; Richter G; Katus HA; Dengler TJ
Eur J Immunol; 2005 Jun; 35(6):1712-21. PubMed ID: 15864782
[TBL] [Abstract][Full Text] [Related]
19. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
20. B7+ iris pigment epithelial cells convert T cells into CTLA-4+, B7-expressing CD8+ regulatory T cells.
Sugita S; Keino H; Futagami Y; Takase H; Mochizuki M; Stein-Streilein J; Streilein JW
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5376-84. PubMed ID: 17122127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
